Tekla Capital Management’s Heron Therapeutics HRTX Stock Holding History

Tekla Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-131,183	Closed	-$2.13M	–	194
2021 Q1	$2.13M	Hold	131,183	–	–	0.07%	160
2020 Q4	$2.78M	Hold	131,183	–	–	0.1%	145
2020 Q3	$1.94M	Hold	131,183	–	–	0.07%	157
2020 Q2	$1.93M	Hold	131,183	–	–	0.07%	163
2020 Q1	$1.54M	Buy	131,183 +71,341	+119%	+$1.34M	0.07%	150
2019 Q4	$1.41M	Buy	+59,842	New	+$1.32M	0.05%	168
2016 Q3	–	Sell	-492,303	Closed	-$8.89M	–	151
2016 Q2	$8.89M	Buy	492,303 +273,303	+125%	+$5.34M	0.36%	63
2016 Q1	$4.16M	Hold	219,000	–	–	0.18%	95
2015 Q4	$5.85M	Hold	219,000	–	–	0.21%	83
2015 Q3	$5.34M	Sell	219,000 -217,970	-50%	-$7.26M	0.19%	98
2015 Q2	$13.6M	Sell	436,970 -436,970	-50%	-$8.22M	0.49%	43
2015 Q1	$12.7M	Hold	873,940	–	–	0.5%	48
2014 Q4	$8.79M	Hold	873,940	–	–	0.41%	56
2014 Q3	$7.28M	Hold	873,940	–	–	0.34%	65
2014 Q2	$10.8M	Buy	873,940 +177,343	+25%	+$2.12M	0.99%	27
2014 Q1	$9.69M	Buy	+696,597	New	+$9.31M	0.97%	28

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Tekla Capital Management's HRTX Position: Q2 2021 in Review

Tekla Capital Management sold out of Heron Therapeutics (HRTX) in Q2 2021, closing a stake of 131,183 shares — an estimated $2.13M sold.

Tekla Capital Management first reported a position in HRTX in Q1 2014 and held it in 16 quarters. The position peaked at $13.6M in Q2 2015. 189 funds tracked by Wall St. Rank hold HRTX as of Q2 2021.

Tekla Capital Management reported no remaining Heron Therapeutics position as of Q2 2021 after selling out during the quarter.
Tekla Capital Management sold 131,183 Heron Therapeutics shares in Q2 2021, an estimated $2.13M.
Tekla Capital Management first reported a position in Heron Therapeutics in Q1 2014 and held it in 16 quarters.
Tekla Capital Management's Heron Therapeutics position peaked at $13.6M in Q2 2015.
189 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2021.

Based on Tekla Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.